Evolus Enters Into Licensing Agreement With Symatese To Exclusively Distribute Next-Generation Dermal Fillers In Europe; Evolus Will Pre-Announce Preliminary, Unaudited Q4 And FY23 Results And Revenue Guidance For 2024 In January
Portfolio Pulse from Benzinga Newsdesk
Evolus, Inc. (NASDAQ:EOLS) has entered into an exclusive licensing agreement with Symatese to distribute four next-generation dermal fillers in the UK and Europe, with regulatory approvals expected in the second half of 2024 and commercialization in 2025. The agreement expands Evolus' international market and complements the launch of Nuceiva, their flagship neurotoxin. Evolus will issue 610,000 shares to Symatese and make milestone payments upon regulatory approvals. The company expects to be fully funded to profitability by 2025 and will pre-announce Q4 and FY23 results and 2024 revenue guidance in January.
December 20, 2023 | 1:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Evolus has secured an exclusive agreement to distribute dermal fillers in Europe, potentially doubling its international market. The company will issue shares to Symatese and anticipates profitability by 2025, with preliminary FY23 results and 2024 guidance coming in January.
The exclusive distribution agreement is a significant expansion for Evolus, likely to be viewed positively by investors as it increases the company's market potential and growth prospects in Europe. The issuance of shares and milestone payments indicate a strong partnership with Symatese, and the anticipation of profitability by 2025 could boost investor confidence. The upcoming pre-announcement of financial results may also influence stock price as it provides insight into the company's performance and future expectations.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100